Correction: A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 &TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review

Correction: A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 &TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review

Saved in:

Bibliographic Details
Main Authors:	Xiangyu Xu, Zheng Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	non-small cell lung cancer (NSCLC) brain metastasis programmed cell death ligand 1 tumor mutational burden (TMB) pathological complete response (PCR) circulating tumor DNA (ctDNA)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1660020/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A stage IV lung squamous cell cancer patient with brain metastases, high PD-L1 & TMB, achieves pCR and long-term survival after immune-chemotherapy and radical surgery: a case report and literature review
by: Xiangyu Xu, et al.
Published: (2025-07-01)

Comparison of level of circulating tumor DNA between oral squamous cell carcinoma and healthy controls: a case control study
by: Samrina Mohammad, et al.
Published: (2025-07-01)

Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer
by: Mengyue Lei, et al.
Published: (2025-06-01)

Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients
by: Dong Lin, et al.
Published: (2025-07-01)

Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study
by: Shuta Ohara, MD, PhD, et al.
Published: (2025-03-01)

The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology
by: Shaivy Malik, et al.
Published: (2025-06-01)

The growing field of liquid biopsy and its Snowball effect on reshaping cancer management
by: Roberto Borea, et al.
Published: (2025-06-01)

Research trends and prospects of Circulating tumor DNA associated with colorectal cancer: a bibliometric analysis
by: Shusen Xia, et al.
Published: (2025-08-01)

Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
by: Simon Heeke, PhD, et al.
Published: (2025-04-01)

Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives
by: Yi Wang, et al.
Published: (2025-07-01)

Clinical Utility of ctDNA Analysis in Lung Cancer—A Review
by: Kamil Makar, et al.
Published: (2025-06-01)

Bibliometric analysis of global research trends and prospects on circulating tumor DNA in colorectal cancer
by: Jing Pang, et al.
Published: (2024-11-01)

Cerebrospinal fluid Circulating Tumor DNA (ctDNA) as a biomarker for CNS metastases in Non-Small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods
by: Oluwatobi O. Olayode, et al.
Published: (2025-07-01)

A novel KRAS exon 2 drop-off digital PCR assay for mutation detection in cell-free DNA of cancer patients
by: Bianca Addamo-De Nard, et al.
Published: (2025-05-01)

Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study
by: Xu Zhang, et al.
Published: (2025-08-01)

Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment
by: Rui FAN, et al.
Published: (2025-05-01)

The importance of circulating tumor products as „liquid biopsies” in colorectal cancer
by: Alina Miscoci, et al.
Published: (2018-04-01)

Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer
by: Young-gon Kim, et al.
Published: (2024-10-01)

The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis
by: Ruoyi Yang, et al.
Published: (2024-11-01)

Recurrence Prediction by Multi-Omics in the Patient with Colorectal Peritoneal Metastases After Cytoreductive Surgery: A Prospective Biomarker Study
by: Chen C, et al.
Published: (2025-04-01)

Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response
by: Iris van 't Erve, PhD, et al.
Published: (2025-09-01)

Editorial: Challenges and advances in carcinomatous meningitis treatment
by: Maciej M. Mrugala, et al.
Published: (2025-08-01)

International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
by: Nicola Fusco, et al.
Published: (2025-06-01)

Journal Watch: Dr Tu looks back at the most important research articles released in 2018 relating to models and biomarkers of hepatocellular carcinoma
by: Thomas Tu
Published: (2019-03-01)

Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
by: Maibritt Nørgaard, et al.
Published: (2025-04-01)

Exploring the Clinical Value of Perioperative ctDNA‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma
by: Jimin Li, et al.
Published: (2025-02-01)

Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
by: Naing Lin Shan, et al.
Published: (2024-12-01)

Circulating Tumor DNA in Primary and Secondary Liver Cancers: A Comprehensive Review
by: Hanna Hong, et al.
Published: (2025-06-01)

Combining the DNA methylation markers of circulating tumor cells with immune infiltrating cells to assess recurrence and prognosis and to suggest a therapeutic strategy in stage III-IV colorectal cancer
by: Juan Zhou, et al.
Published: (2025-07-01)

Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy
by: Prithvi B. Murthy, et al.
Published: (2023-07-01)

Integration of Circulating Tumor DNA and Metabolic Parameters on 18F‐Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non‐Small Cell Lung Cancer
by: Leilei Wu, et al.
Published: (2025-04-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Circulating tumor DNA (ctDNA) Detection via electrochemical Biosensing Tools
by: Sonya Sahin, et al.
Published: (2024-06-01)

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
by: Andrew G. Hadd, et al.
Published: (2025-03-01)

The emerging role of circulating tumor DNA in brain tumor research
by: Amir Modarresi Chahardehi, et al.
Published: (2025-06-01)

Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
by: Arter ZL, et al.
Published: (2025-02-01)

Role of circulating tumor DNA and cell-free DNA biomarkers in diagnosis and prognosis of oral cancer - a systematic review
by: Samrina Mohammad, et al.
Published: (2025-04-01)

Circulating Tumor DNA Dynamic Changes in Esophageal Squamous Cell Carcinoma Receiving Immunochemotherapy
by: Yijia Guo, et al.
Published: (2025-05-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

The Role of Circulating Tumor DNA and Cell-Free DNA in the Management of Germ Cell Tumors: A Narrative Review
by: Isabella Dolendo, et al.
Published: (2023-07-01)